Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

Author(s):

Robert M. Rifkin, MD, FACP, discusses how the MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition sheds light on elranatamab’s role in relapsed/refractory multiple myeloma while panelists discuss how emerging data on bispecific antibodies and combination strategies could shape treatment timing and improve outcomes, especially in heavily pretreated patients.

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

Now Viewing

EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

Video content above is prompted by the following:

The MagnetisMM-3 update at the 66th American Society of Hematology Annual Meeting and Exposition provided critical insights into elranatamab for patients with relapsed/refractory multiple myeloma. What are your key takeaways from this update, and how do these data influence the role of elranatamab in the current treatment paradigm?
With growing data on bispecifics, what are your perspectives on the ideal timing for integrating these therapies into treatment plans, especially in heavily pretreated patients vs earlier lines?
There is increasing interest in combining bispecific antibodies with other therapies. Which combination strategies do you find most promising, and what potential do they hold for enhancing outcomes in relapsed/refractory multiple myeloma?